BioSpace News Archive

A peer-reviewed research article published today in the Journal of Experimental Medicine, titled “Blood plasma phosphorylated-tau isoforms track CNS [central nervous system] change in Alzheimer’s disease,” finds that the brain protein tau phosphorylated at position 217 (p-tau217) is measurable in blood by mass spectrometry and that this form of tau is a powerful early indicator of Alzheimer’s disease.

March of Dimes, the nation’s leader in the fight for the health of all moms and babies, and The Humana Foundation, the philanthropic arm of Humana Inc. are working together to address the racial disparities and social determinants of health that contribute to the U.S. maternal and infant health crisis.

GSK today announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2020-21 flu season

TearLab Corporation (TearLab), an eye care medical device firm marketing lab-on-a-chip diagnostic technologies at the point-of-care, today announced the appointment of Adam Szaronos to the position of Chief Commercial Officer (CCO).

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2020.

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference to be held August 11-12, 2020.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.